Embolotherapy Market by Product (Embolic Agents (Microspheres, Detachable Coils, Pushable Coils), Guidewires), Disease (Oncology, Aneurysm, Peripheral Vascular), Procedure, End User (Hospitals, Clinics, ASC, Academia) - Global Forecast to 2024

塞栓療法の世界市場予測(~2024年)

◆タイトル:Embolotherapy Market by Product (Embolic Agents (Microspheres, Detachable Coils, Pushable Coils), Guidewires), Disease (Oncology, Aneurysm, Peripheral Vascular), Procedure, End User (Hospitals, Clinics, ASC, Academia) - Global Forecast to 2024
◆商品コード:MAM90919
◆調査・発行会社:MarketsandMarkets
◆発行日:2019年8月18日
◆ページ数:220
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD5,650 ⇒換算¥610,200見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥718,200見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥880,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

当調査レポートでは、塞栓療法の世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、産業動向、市場シェア分析、製品別(塞栓剤(ミクロスフィア、取り外し可能コイル、プッシュ可能コイル)、ガイドワイヤー)分析、疾患別(腫瘍学、動脈瘤、末梢血管)分析、処置別分析、エンドユーザー別(病院、診療所、ASC、学界)分析、塞栓療法の世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。MarketsandMarkets社は、塞栓療法の世界市場規模が2019年33億ドルから2024年49億ドルまで年平均8.1%成長すると予測しています。

“The embolotherapy market is projected to grow at a CAGR of 8.1% during the forecast period”The embolotherapy market is projected to reach USD 4.9 billion by 2024 from USD 3.3 billion in 2019, at a CAGR of 8.1% from 2019 to 2024. The growth of this market is primarily driven by the rising burden of target diseases and increasing investments, funds, and grants for the development of novel products. Moreover, increasing demand for minimally invasive procedures, favorable reimbursement scenario, and new product launches in the market are further supporting the growth of the market over the forecast period. However, stringent regulatory frameworks for product commercialization and the strong market positioning of alternative treatments are expected to limit the optimal adoption of embolotherapy devices during the forecast period.

“The cancer segment, by disease indication, accounted for the largest share of the embolotherapy market in 2018”
In terms of disease indication, embolotherapy market is classified into cancer, peripheral vascular diseases, neurological diseases, urological & nephrological disorders, and gastrointestinal disorders. The high success rate and less post-operative complication rate associated with embolotherapy procedures coupled with the rising incidences of liver cancer and hepatocellular cancer are the key factors fueling the demand for embolotherapy devices for cancer disease indication. For instance, liver cancer is the fifth most common cancer in men and the ninth most common in women.

“The embolic agents segment, by product, is to register a significant growth rate owing to new product approvals”
Based on product, the embolotherapy market is broadly segmented into embolic agents and support devices. The embolic agents segment is further subsegmented into embolic coils, embolic plug systems, liquid embolic agents, microspheres, and detachable balloons. Whereas, the support devices segment includes microcatheters and guidewires. The embolic agents segment is anticipated to register the highest growth over the forecast period owing to new product approvals and launches in the segment. For instance, in 2019, Terumo received the FDA Premarket Approval (PMA) for the ‘WEB Aneurysm Embolization System.’ Moreover, in 2018, Medtronic launched OptiSphere embolization spheres in the US as well as the Concerto 3D detachable coil system in Ireland.

“The US market, by region, commanded the largest market share in 2018”
On the basis of region, the embolotherapy market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The US held the major share of the global embolotherapy market in 2018. Factors such as the favorable reimbursement scenario in the US, growing target patient population (CVDs, neurovascular diseases, cancer, and uterine fibroids), increasing preference for minimally invasive procedures, new product launches and technological advancements in embolotherapy devices, and the presence of key players in the region are driving the growth of the embolotherapy market in the US.

Breakdown of supply-side primary interviews:
• By Company Type: Tier 1 – 25%, Tier 2 – 30%, and Tier 3 – 45%
• By Designation: C-level – 26%, Director-level – 30%, and Others – 44%
• By Country: North America- 34%, Europe – 26%, APAC – 23%, and RoW – 17%

The major players in the market include Boston Scientific Corporation (US), Merit Medical Systems (US), Terumo Corporation (Japan), Medtronic plc (Ireland), Johnson & Johnson (US), Stryker Corporation (US), BTG plc (UK), Penumbra, Inc. (US), Cook Medical (US), Abbott Laboratories (US), Acandis GmbH (Germany), BALT Extrusion (France), Sirtex Medical Limited (Australia), Kaneka Corporation (Japan), and Meril Life Sciences Pvt. Ltd. (India) among others.

Research Coverage
This report studies the embolotherapy market based on product, disease indication, procedure, end user, and region. The report also studies factors such as drivers, restraints, opportunities, and challenges affecting market growth. It also provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to individual growth trends, and it also forecasts the revenue of the market segments with respect to four main countries.

Key Benefits of Buying the Report
This report focuses on various levels of analysis—industry trends, market shares of top players, and company profiles, which together form basic views. It also analyzes the competitive landscape; and high-growth countries along with their respective drivers, restraints, challenges, and opportunities. The report will help both established firms as well as new entrants/smaller firms to gauge the pulse of the market and garner greater market shares.

【レポートの目次】

1 Introduction (Page No. – 20)
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered for the Study
1.4 Currency
1.5 Limitations
1.6 Stakeholders
2 Research Methodology (Page No. – 24)
2.1 Research Data
2.1.1 Secondary Data
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Data
2.1.2.1 Key Data From Primary Sources
2.2 Market Size Estimation
2.2.1 Product-Based Market Estimation
2.2.2 Primary Research Validation
2.3 Market Breakdown and Data Triangulation
2.4 Research Assumptions
2.5 Research Limitations
3 Executive Summary (Page No. – 35)
4 Premium Insights (Page No. – 39)
4.1 Embolotherapy: Market Overview
4.2 Embolotherapy Market, By Product
4.3 Market, By Procedure and Region
4.4 Market, By Disease Indication
4.5 Asia Pacific Market, By End User aand Country
4.6 Geographic Snapshot of the Market
5 Market Overview (Page No. – 45)
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Growing Target Patient Population
5.2.1.2 Rising Patient Preference for Minimally Invasive Procedures
5.2.1.3 Funding & Investments By Government and Private Organizations
5.2.1.4 Technological Advancements in Embolotherapy Devices
5.2.1.5 Favorable Reimbursement Scenario for Minimally Invasive Surgeries
5.2.2 Restraints
5.2.2.1 Lack of Sufficient Evidence & Unfavorable Regulatory Scenario
5.2.2.2 Strong Market Positioning of Alternative Therapies
5.2.3 Opportunities
5.2.3.1 Growth Opportunities Offered By Emerging Markets
5.2.3.2 Expanding Applications of Embolization Devices
5.2.4 Challenges
5.2.4.1 Dearth of Skilled Surgeons
5.2.4.2 High Costs and Resulting Difficulties in Accessing Embolization in Developing Countries
6 Embolotherapy Market, By Product (Page No. – 54)
6.1 Introduction
6.2 Embolic Agents
6.2.1 Microspheres
6.2.1.1 Preference for Alternative Procedures Limits the Growth of This Market Segment
6.2.2 Embolic Coils
6.2.2.1 Detachable Coils
6.2.2.1.1 Detachable Coils Can Be Retracted and Redeployed A Number of Times Until Satisfactory Placement is Reached, Which is A Key Advantage of This Product Segment
6.2.2.2 Pushable Coils
6.2.2.2.1 Use of Pushable Coils Increases the Risk of Non-Target Vascular Blockages, Thereby Hampering Their Use in Various Applications
6.2.3 Liquid Embolic Agents
6.2.3.1 Significant Adoption of Embolic Coils Due to Their Procedural Benefits Over Liquid Embolic Agents is Expected to Restrict Market Growth
6.2.4 Embolic Plug Systems
6.2.4.1 Procedural Advantages Delivered By Vascular Plugs Such as A Significantly Shorter Occlusion Time and Recanalization Rate are the Key Factors Leading to Their Increased Adoption
6.2.5 Detachable Balloons
6.2.5.1 Adverse Events Associated With the Use of Detachable Balloons Such as Balloon Rupture, Failure, Or Shrinkage May Limit the Utilization of This Embolic Device
6.3 Support Devices
6.3.1 Microcatheters
6.3.1.1 Advancements and Regulatory Approvals in Microcatheter Technologies are Expected to Result in Their Wider Adoption
6.3.2 Guidewires
6.3.2.1 Rising Adoption of Guidewires Among Medical Professionals Owing to Their Procedural Benefits is Expected to Drive Market Growth
7 Embolotherapy Market, By Disease Indication (Page No. – 70)
7.1 Introduction
7.2 Cancer
7.2.1 Liver Cancer
7.2.1.1 Rising Prevalence of Liver Cancer is Projected to Fuel Segment Growth
7.2.2 Kidney Cancer
7.2.2.1 The Wide Adoption of Preoperative Kidney Tumor Embolization in the Treatment of Kidney Cancer is Driving Market Growth
7.2.3 Other Cancers
7.2.3.1 Increasing Clinical Research to Check the Effectiveness of Embolization for Cancer Treatment to Drive Market Growth
7.3 Peripheral Vascular Disease
7.3.1 Rising Adoption of Vascular Plugs is A Key Driving Factor for the Market
7.4 Neurological Diseases
7.4.1 Cerebral Aneurysm
7.4.1.1 Limited Availability of Reimbursements Across Major Markets May Hinder Market Growth
7.4.2 Arteriovenous Malformation and Fistulas
7.4.2.1 Side Effects Associated With AVM Embolization Procedures May Restrict Market Growth to A Certain Extent
7.5 Urological & Nephrological Disorders
7.5.1 Embolic Agents are Used to Treat Uterine Fibroids, Autosomal Dominant Polycystic Kidney Disease, and Benign Prostatic Hyperplasia
7.6 Gastrointestinal Disorders
7.6.1 Embolization is A Widely Adopted Procedure Used to Treat LGIB and LGIB
8 Embolotherapy Market, By Procedure (Page No. – 83)
8.1 Introduction
8.2 Transcatheter Arterial Embolization (TAE)
8.2.1 Transcatheter Arterial Embolization Dominates the Market Due to the Increasing Incidence of Uterine Fibroids & Vascular Lesions
8.3 Transcatheter Arterial Radioembolization (TARE)/Selective Internal Radiation Therapy (SIRT)
8.3.1 Better Clinical Outcomes & Increased Cancer Survival Rate are Supporting the Growth of This Segment
8.4 Transarterial Chemoembolization (TACE)
8.4.1 TACE Can Be Used to Treat Tumors That are Relatively Larger in Size, Which Cannot Be Easily Treated By Tumor Ablation
9 Embolotherapy Market, By End User (Page No. – 89)
9.1 Introduction
9.2 Hospitals and Clinics
9.3 Ambulatory Surgery Centers
9.4 Other End Users
10 Embolotherapy Market, By Region (Page No. – 94)
10.1 Introduction
10.2 North America
10.2.1 US
10.2.1.1 The US Dominates the Global Market in 2018 Due to the Large R&D Investments in the Country
10.2.2 Canada
10.2.2.1 High Burden of Cancer to Support Market Growth
10.3 Europe
10.3.1 Germany
10.3.1.1 Germany is the Fastest-Growing Market in Europe
10.3.2 UK
10.3.2.1 Increasing Incidence of Target Health Conditions Coupled With the Rising Geriatric Population to Drive Market Growth
10.3.3 France
10.3.3.1 Government Initiatives to Raise Awareness About Embolotherapy Will Increase the Adoption of Embolization Procedures in the Country
10.3.4 Rest of Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.1.1 Growing Geriatric Population and the Increasing R&D Investments in the Country are the Major Factors Driving Market Growth
10.4.2 China
10.4.2.1 China to Register the Highest Growth in the APAC Embolotherapy Market Due to the Growing Target Patient Population
10.4.3 India
10.4.3.1 Ongoing Modernization and Expansion of Healthcare Infrastructure and Growing Medical Tourism to Support Market Growth
10.4.4 Rest of Asia Pacific
10.5 Latin America
10.5.1 Brazil
10.5.1.1 Increasing Incidence of Hepatocellular Carcinoma and Cerebral Aneurysm to Drive the Adoption of Embolization Products
10.5.2 Rest of Latin America
10.6 Middle East & Africa
11 Competitive Landscape (Page No. – 173)
11.1 Introduction
11.2 Market Share Analysis
11.2.1 Market Share Analysis for Microspheres (2018)
11.2.2 Market Share Analysis for Embolization Coils (2018)
11.3 Competitive Situation and Trends
11.4 Competitive Leadership Mapping
11.5 Vendor Inclusion Criteria
11.6 Vendor Dive
11.6.1 Visionary Leaders
11.6.2 Innovators
11.6.3 Dynamic Differentiators
11.6.4 Emerging Players
12 Company Profiles (Page No. – 180)
12.1 Abbott Laboratories
12.2 Acandis GmbH
12.3 Balt Extrusion
12.4 Boston Scientific Corporation
12.5 BTG PLC
12.6 Cook Medical
12.7 Johnson & Johnson
12.8 Kaneka Corporation
12.9 Medtronic PLC
12.10 Meril Life Sciences Pvt., Ltd.
12.11 Merit Medical Systems
12.12 Penumbra, Inc.
12.13 Sirtex Medical Limited
12.14 Stryker Corporation
12.15 Terumo Corporation
13 Appendix (Page No. – 210)
13.1 Discussion Guide
13.2 Knowledge Store: Marketsandmarkets’ Subscription Portal
13.3 Available Customizations
13.4 Related Reports
13.5 Author Details

List of Tables (184 Tables)
Table 1 Primary Liver Cancer Incidence Among Men and Women (2005 vs 2030)
Table 2 Geriatric Population, By Region, 2015 vs 2030
Table 3 Medical Reimbursement Cpt Codes for Embolization Procedures in the US (Effective From January 2019)
Table 4 Medical Reimbursement Ms-Drg Codes for Embolization Procedures in the US (Effective From January 2019)
Table 5 Embolotherapy Market, By Product, 2017–2024 (USD Million)
Table 6 Market for Embolic Agents, By Type, 2017–2024 (USD Million)
Table 7 Market for Embolic Agents, By Region, 2017–2024 (USD Million)
Table 8 Embolic Agents, By Type
Table 9 Market for Microspheres, By Region, 2017–2024 (USD Million)
Table 10 Embolic Coils Offered By Major Market Players
Table 11 Market for Embolic Coils, By Type, 2017–2024 (USD Million)
Table 12 Market for Embolic Coils, By Region, 2017–2024 (USD Million)
Table 13 Market for Detachable Coils, By Region, 2017–2024 (USD Million)
Table 14 Market for Pushable Coils, By Region, 2017–2024 (USD Million)
Table 15 Embolotherapy Market for Liquid Embolic Agents, By Region, 2017–2024 (USD Million)
Table 16 Market for Embolic Plug Systems, By Region, 2017–2024 (USD Million)
Table 17 Market for Detachable Balloons, By Region, 2017–2024 (USD Million)
Table 18 Market for Support Devices, By Type, 2017–2024 (USD Million)
Table 19 Market for Support Devices, By Region, 2017–2024 (USD Million)
Table 20 Market for Microcatheters, By Region, 2017–2024 (USD Million)
Table 21 Market for Guidewires, By Region, 2017–2024 (USD Million)
Table 22 Market, By Disease Indication, 2017–2024
Table 23 Embolotherapy Market for Cancer, By Type, 2017–2024
Table 24 Market for Cancer, By Region, 2017–2024
Table 25 Market for Liver Cancer, By Region, 2017–2024 (USD Million)
Table 26 Market for Kidney Cancer, By Region, 2017–2024 (USD Million)
Table 27 Market for Other Cancers, By Region, 2017–2024 (USD Million)
Table 28 Market for Peripheral Vascular Diseases, By Region, 2017–2024 (USD Million)
Table 29 Embolotherapy Market for Neurological Diseases, By Type, 2017–2024
Table 30 Market for Neurological Diseases, By Region, 2017–2024 (USD Million)
Table 31 Market for Cerebral Aneurysms, By Region, 2017–2024 (USD Million)
Table 32 Market for Arteriovenous Malformation & Fistulas, By Region, 2017–2024 (USD Million)
Table 33 Market for Urological & Nephrological Diseases, By Region, 2017–2024 (USD Million)
Table 34 Market for Gastrointestinal Disorders, By Region, 2017–2024 (USD Million)
Table 35 Embolotherapy Market, By Procedure, 2017–2024 (USD Million)
Table 36 Transcatheter Arterial Embolization Market, By Region, 2017–2024 (USD Million)
Table 37 Transcatheter Arterial Radioembolization Market, By Region, 2017–2024 (USD Million)
Table 38 Transarterial Chemoembolization Market, By Region, 2017–2024
Table 39 Market, By End User, 2017–2024 (USD Million)
Table 40 Market for Hospitals and Clinics, By Region, 2017–2024 (USD Million)
Table 41 Market for Ambulatory Surgery Centers, By Region, 2017–2024 (USD Million)
Table 42 Embolotherapy Market for Other End Users, By Region, 2017–2024 (USD Million)
Table 43 Market, By Region, 2017–2024 (USD Million)
Table 44 North America: Market, By Country, 2017–2024 (USD Million)
Table 45 North America: Market, By Product, 2017–2024 (USD Million)
Table 46 North America: Market for Embolic Agents, By Type, 2017–2024 (USD Million)
Table 47 North America: Market for Embolic Coils, By Type, 2017–2024 (USD Million)
Table 48 North America: Market for Support Devices, By Type, 2017–2024 (USD Million)
Table 49 North America: Market, By Disease Indication, 2017–2024 (USD Million)
Table 50 North America: Market for Cancer, By Type, 2017–2024 (USD Million)
Table 51 North America: Market for Neurological Diseases, By Type, 2017–2024 (USD Million)
Table 52 North America: Market, By Procedure, 2017–2024 (USD Million)
Table 53 North America: Market, By End User, 2017–2024 (USD Million)
Table 54 Medicare Reimbursement for Transcatheter Embolization Or Occlusion Services: 2019
Table 55 US: Market, By Product, 2017–2024 (USD Million)
Table 56 US: Market for Embolic Agents, By Type, 2017–2024 (USD Million)
Table 57 US: Embolotherapy Market for Embolic Coils, By Type, 2017–2024 (USD Million)
Table 58 US: Market for Support Devices, By Type, 2017–2024 (USD Million)
Table 59 US: Market, By Disease Indication, 2017–2024 (USD Million)
Table 60 US: Market, By Procedure, 2017–2024 (USD Million)
Table 61 US: Market, By End User, 2017–2024 (USD Million)
Table 62 Canada: Market, By Product, 2017–2024 (USD Million)
Table 63 Canada: Embolotherapy Market for Embolic Agents, By Type, 2017–2024 (USD Million)
Table 64 Canada: Market for Embolic Coils, By Type, 2017–2024 (USD Million)
Table 65 Canada: Market for Support Devices, By Type, 2017–2024 (USD Million)
Table 66 Canada: Market, By Disease Indication, 2017–2024 (USD Million)
Table 67 Canada: Market, By Procedure, 2017–2024 (USD Million)
Table 68 Canada: Market, By End User, 2017–2024 (USD Million)
Table 69 Europe: Market, By Country, 2017–2024 (USD Million)
Table 70 Europe: Market, By Product, 2017–2024 (USD Million)
Table 71 Europe: Market for Embolic Agents, By Type, 2017–2024 (USD Million)
Table 72 Europe: Market for Embolic Coils, By Type, 2017–2024 (USD Million)
Table 73 Europe: Embolotherapy Market for Support Devices, By Type, 2017–2024 (USD Million)
Table 74 Europe: Market, By Disease Indication, 2017–2024 (USD Million)
Table 75 Europe: Market for Cancer, By Type, 2017–2024 (USD Million)
Table 76 Europe: Market for Neurological Diseases, By Type, 2017–2024 (USD Million)
Table 77 Europe: Market, By Procedure, 2017–2024 (USD Million)
Table 78 Europe: Market, By End User, 2017–2024 (USD Million)
Table 79 Germany: Embolotherapy Market, By Product, 2017–2024 (USD Million)
Table 80 Germany: Market for Embolic Agents, By Type, 2017–2024 (USD Million)
Table 81 Germany: Market for Embolic Coils, By Type, 2017–2024 (USD Million)
Table 82 Germany: Market for Support Devices, By Type, 2017–2024 (USD Million)
Table 83 Germany: Market, By Disease Indication, 2017–2024 (USD Million)
Table 84 Germany: Market, By Procedure, 2017–2024 (USD Million)
Table 85 Germany: Market, By End User, 2017–2024 (USD Million)
Table 86 UK: Embolotherapy Market, By Product, 2017–2024 (USD Million)
Table 87 UK: Market for Embolic Agents, By Type, 2017–2024 (USD Million)
Table 88 UK: Market for Embolic Coils, By Type, 2017–2024 (USD Million)
Table 89 UK: Market for Support Devices, By Type, 2017–2024 (USD Million)
Table 90 UK: Market, By Disease Indication, 2017–2024 (USD Million)
Table 91 UK: Market, By Procedure, 2017–2024 (USD Million)
Table 92 UK: Market, By End User, 2017–2024 (USD Million)
Table 93 France: Market, By Product, 2017–2024 (USD Million)
Table 94 France: Embolotherapy Market for Embolic Agents, By Type, 2017–2024 (USD Million)
Table 95 France: Market for Embolic Coils, By Type, 2017–2024 (USD Million)
Table 96 France: Market for Support Devices, By Type, 2017–2024 (USD Million)
Table 97 France: Market, By Disease Indication, 2017–2024 (USD Million)
Table 98 France: Market, By Procedure, 2017–2024 (USD Million)
Table 99 France: Market, By End User, 2017–2024 (USD Million)
Table 100 RoE: Health Expenditure, By Country (2017)
Table 101 Aging Population (% Share of the Total Population), By Country, 2015 vs 2030 (In Million)
Table 102 Cancer Incidence, By Country, 2018
Table 103 RoE: Embolotherapy Market, By Product, 2017–2024 (USD Million)
Table 104 RoE: Market for Embolic Agents, By Type, 2017–2024 (USD Million)
Table 105 RoE: Market for Embolic Coils, By Type, 2017–2024 (USD Million)
Table 106 RoE: Market for Support Devices, By Type, 2017–2024 (USD Million)
Table 107 RoE: Market, By Disease Indication, 2017–2024 (USD Million)
Table 108 RoE: Market, By Procedure, 2017–2024 (USD Million)
Table 109 RoE: Market, By End User, 2017–2024 (USD Million)
Table 110 Asia Pacific: Embolotherapy Market, By Country, 2017–2024 (USD Million)
Table 111 Asia Pacific: Market, By Product, 2017–2024 (USD Million)
Table 112 Asia Pacific: Market for Embolic Agents, By Type, 2017–2024 (USD Million)
Table 113 Asia Pacific: Market for Embolic Coils, By Type, 2017–2024 (USD Million)
Table 114 Asia Pacific: Market for Support Devices, By Type, 2017–2024 (USD Million)
Table 115 Asia Pacific: Market, By Disease Indication, 2017–2024 (USD Million)
Table 116 Asia Pacific: Market for Cancer, By Type, 2017–2024 (USD Million)
Table 117 Asia Pacific: Embolotherapy Market for Neurological Diseases, By Type, 2017–2024 (USD Million)
Table 118 Asia Pacific: Market, By Procedure, 2017–2024 (USD Million)
Table 119 Asia Pacific: Market, By End User, 2017–2024 (USD Million)
Table 120 Japan: Market, By Product, 2017–2024 (USD Million)
Table 121 Japan: Market for Embolic Agents, By Type, 2017–2024 (USD Million)
Table 122 Japan: Market for Embolic Coils, By Type, 2017–2024 (USD Million)
Table 123 Japan: Market for Support Devices, By Type, 2017–2024 (USD Million)
Table 124 Japan: Embolotherapy Market, By Disease Indication, 2017–2024 (USD Million)
Table 125 Japan: Market, By Procedure, 2017–2024 (USD Million)
Table 126 Japan: Market, By End User, 2017–2024 (USD Million)
Table 127 China: Market, By Product, 2017–2024 (USD Million)
Table 128 China: Market for Embolic Agents, By Type, 2017–2024 (USD Million)
Table 129 China: Market for Embolic Coils, By Type, 2017–2024 (USD Million)
Table 130 China: Market for Support Devices, By Type, 2017–2024 (USD Million)
Table 131 China: Embolotherapy Market, By Disease Indication, 2017–2024 (USD Million)
Table 132 China: Market, By Procedure, 2017–2024 (USD Million)
Table 133 China: Market, By End User, 2017–2024 (USD Million)
Table 134 India: Market, By Product, 2017–2024 (USD Million)
Table 135 India: Market for Embolic Agents, By Type, 2017–2024 (USD Million)
Table 136 India: Market for Embolic Coils, By Type, 2017–2024 (USD Million)
Table 137 India: Market for Support Devices, By Type, 2017–2024 (USD Million)
Table 138 India: Embolotherapy Market, By Disease Indication, 2017–2024 (USD Million)
Table 139 India: Market, By Procedure, 2017–2024 (USD Million)
Table 140 India: Market, By End User, 2017–2024 (USD Million)
Table 141 RoAPAC: Market, By Product, 2017–2024 (USD Million)
Table 142 RoAPAC: Market for Embolic Agents, By Type, 2017–2024 (USD Million)
Table 143 RoAPAC: Market for Embolic Coils, By Type, 2017–2024 (USD Million)
Table 144 RoAPAC: Market for Support Devices, By Type, 2017–2024 (USD Million)
Table 145 RoAPAC: Embolotherapy Market, By Disease Indication, 2017–2024 (USD Million)
Table 146 RoAPAC: Market, By Procedure, 2017–2024 (USD Million)
Table 147 RoAPAC: Market, By End User, 2017–2024 (USD Million)
Table 148 Latin America: Market, By Country, 2017–2024 (USD Million)
Table 149 Latin America: Market, By Product, 2017–2024 (USD Million)
Table 150 Latin America: Embolotherapy Market for Embolic Agents, By Type, 2017–2024 (USD Million)
Table 151 Latin America: Market for Embolic Coils, By Type, 2017–2024 (USD Million)
Table 152 Latin America: Market for Support Devices, By Type, 2017–2024 (USD Million)
Table 153 Latin America: Market, By Disease Indication, 2017–2024 (USD Million)
Table 154 Latin America: Embolotherapy Market for Cancer, By Type, 2017–2024 (USD Million)
Table 155 Latin America: Market for Neurological Diseases, By Type, 2017–2024 (USD Million)
Table 156 Latin America: Market, By Procedure, 2017–2024 (USD Million)
Table 157 Latin America: Market, By End User, 2017–2024 (USD Million)
Table 158 Brazil: Market, By Product, 2017–2024 (USD Million)
Table 159 Brazil: Market for Embolic Agents, By Type, 2017–2024 (USD Million)
Table 160 Brazil: Embolotherapy Market for Embolic Coils, By Type, 2017–2024 (USD Million)
Table 161 Brazil: Market for Support Devices, By Type, 2017–2024 (USD Million)
Table 162 Brazil: Market, By Disease Indication, 2017–2024 (USD Million)
Table 163 Brazil: Market, By Procedure, 2017–2024 (USD Million)
Table 164 Brazil: Embolotherapy Market, By End User, 2017–2024 (USD Million)
Table 165 RoLA: Market, By Product, 2017–2024 (USD Million)
Table 166 RoLA: Market for Embolic Agents, By Type, 2017–2024 (USD Million)
Table 167 RoLA: Market for Embolic Coils, By Type, 2017–2024 (USD Million)
Table 168 RoLA: Embolotherapy Market for Support Devices, By Type, 2017–2024 (USD Million)
Table 169 RoLA: Market, By Disease Indication, 2017–2024 (USD Million)
Table 170 RoLA: Embolotherapy Market, By Procedure, 2017–2024 (USD Million)
Table 171 RoLA: Market, By End User, 2017–2024 (USD Million)
Table 172 Middle East & Africa: Market, By Product, 2017–2024 (USD Million)
Table 173 Middle East & Africa: Market for Embolic Agents, By Type, 2017–2024 (USD Million)
Table 174 Middle East & Africa: Embolotherapy Market for Embolic Coils, By Type, 2017–2024 (USD Million)
Table 175 Middle East & Africa: Market for Support Devices, By Type, 2017–2024 (USD Million)
Table 176 Middle East & Africa: Market, By Disease Indication, 2017–2024 (USD Million)
Table 177 Middle East & Africa: Market for Cancer, By Type, 2017–2024 (USD Million)
Table 178 Middle East & Africa: Market for Neurological Diseases, By Type, 2017–2024 (USD Million)
Table 179 Middle East & Africa: Market, By Procedure, 2017–2024 (USD Million)
Table 180 Middle East & Africa: Embolotherapy Market, By End User, 2017–2024 (USD Million)
Table 181 Product Launches and Approvals
Table 182 Collaborations
Table 183 Expansions
Table 184 Acquisitions

List of Figures (37 Figures)
Figure 1 Embolotherapy Market: Research Methodology Steps
Figure 2 Research Design
Figure 3 Breakdown of Primaries: Market
Figure 4 Research Methodology: Hypothesis Building
Figure 5 Bottom-Up Approach Market Size Estimation: Market
Figure 6 Top-Down Approach Market Size Estimation: Embolotherapy Market
Figure 7 Data Triangulation Methodology
Figure 8 Market, By Product, 2019–2024 (USD Million)
Figure 9 Market Share, By Disease Indication, 2019 vs 2024
Figure 10 Market Share, By Procedure, 2019–2024 (USD Million)
Figure 11 Market, By End User, 2019–2024 (USD Million)
Figure 12 Embolotherapy Market, By Region: Geographical Snapshot
Figure 13 Rising Incidence of Chronic Diseases is Driving the Growth of the Embolotherapy Market Across the Globe
Figure 14 Microspheres Segment Will Witness High Growth in the Market
Figure 15 Transcatheter Arterial Embolization Segment to Dominate the North American Market in 2019
Figure 16 Cancer Segment to Dominate the Market During the Forecast Period
Figure 17 Ambulatory Surgery Centers Segment Will Register the Highest CAGR in Asia Pacific
Figure 18 China to Register the Highest CAGR During the Forecast Period
Figure 19 Market: Drivers, Restraints, Opportunities, and Challenges
Figure 20 North America: Market Snapshot
Figure 21 Europe: Embolotherapy Market Snapshot
Figure 22 Asia Pacific: Market Snapshot
Figure 23 Key Developments in the Market From 2015 to 2019
Figure 24 BTG PLC Accounted for the Largest Share of the Microspheres Market in 2018
Figure 25 Stryker Held the Leading Position of the Embolization Coils Market in 2018
Figure 26 Market:Global Competitive Leadership Mapping, 2018
Figure 27 Abbott Laboratories: Company Snapshot
Figure 28 Boston Scientific Corporation: Company Snapshot
Figure 29 BTG PLC: Company Snapshot
Figure 30 Johnson & Johnson: Company Snapshot
Figure 31 Kaneka Corporation: Company Snapshot
Figure 32 Medtronic PLC: Company Snapshot
Figure 33 Merit Medical Systems: Company Snapshot
Figure 34 Penumbra, Inc.: Company Snapshot
Figure 35 Sirtex Medical Limited: Company Snapshot
Figure 36 Stryker Corporation: Company Snapshot
Figure 37 Terumo Corporation: Company Snapshot

★調査レポート[塞栓療法の世界市場予測(~2024年)] ( Embolotherapy Market by Product (Embolic Agents (Microspheres, Detachable Coils, Pushable Coils), Guidewires), Disease (Oncology, Aneurysm, Peripheral Vascular), Procedure, End User (Hospitals, Clinics, ASC, Academia) - Global Forecast to 2024 / MAM90919) 販売に関する免責事項
[塞栓療法の世界市場予測(~2024年)] ( Embolotherapy Market by Product (Embolic Agents (Microspheres, Detachable Coils, Pushable Coils), Guidewires), Disease (Oncology, Aneurysm, Peripheral Vascular), Procedure, End User (Hospitals, Clinics, ASC, Academia) - Global Forecast to 2024 / MAM90919) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆